News

Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers core revenue growth has ‘slowed sharply,’ says BofA
BofA analyst Allen Lutz estimates Hims & Hers’ year-over-year core revenue growth has “slowed sharply,” from about 45% in Q3 of 2024 to 29% in Q1 of 2025, despite a tailwind from shifting customers to ...
Why Hims & Hers Health Stock Is Crashing Today
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
sharewise9m
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key ...
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
These Stocks Moved the Most Today: Tesla, Hims & Hers, Wolfspeed, Super Micro, Fiserv, Northrop, Northern Trust, and More
Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, ...